TY - JOUR T1 - Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidances from Regulatory Agencies: Focus on CYP3A4 mRNA In Vitro Response Thresholds, Variability, and Clinical Relevance JF - Drug Metabolism and Disposition JO - Drug Metab Dispos SP - 1285 LP - 1303 DO - 10.1124/dmd.118.081927 VL - 46 IS - 9 AU - Jane R. Kenny AU - Diane Ramsden AU - David B. Buckley AU - Shannon Dallas AU - Conrad Fung AU - Michael Mohutsky AU - Heidi J. Einolf AU - Liangfu Chen AU - Joshua G. Dekeyser AU - Maria Fitzgerald AU - Theunis C. Goosen AU - Y. Amy Siu AU - Robert L. Walsky AU - George Zhang AU - Donald Tweedie AU - Niresh Hariparsad Y1 - 2018/09/01 UR - http://dmd.aspetjournals.org/content/46/9/1285.abstract N2 - The Innovation and Quality Induction Working Group presents an assessment of best practice for data interpretation of in vitro induction, specifically, response thresholds, variability, application of controls, and translation to clinical risk assessment with focus on CYP3A4 mRNA. Single concentration control data and Emax/EC50 data for prototypical CYP3A4 inducers were compiled from many human hepatocyte donors in different laboratories. Clinical CYP3A induction and in vitro data were gathered for 51 compounds, 16 of which were proprietary. A large degree of variability was observed in both the clinical and in vitro induction responses; however, analysis confirmed in vitro data are able to predict clinical induction risk. Following extensive examination of this large data set, the following recommendations are proposed. a) Cytochrome P450 induction should continue to be evaluated in three separate human donors in vitro. b) In light of empirically divergent responses in rifampicin control and most test inducers, normalization of data to percent positive control appears to be of limited benefit. c) With concentration dependence, 2-fold induction is an acceptable threshold for positive identification of in vitro CYP3A4 mRNA induction. d) To reduce the risk of false positives, in the absence of a concentration-dependent response, induction ≥ 2-fold should be observed in more than one donor to classify a compound as an in vitro inducer. e) If qualifying a compound as negative for CYP3A4 mRNA induction, the magnitude of maximal rifampicin response in that donor should be ≥ 10-fold. f) Inclusion of a negative control adds no value beyond that of the vehicle control. ER -